Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 6
2022 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T. Iida K, et al. Among authors: isobe t. Sci Rep. 2024 Jan 30;14(1):2520. doi: 10.1038/s41598-024-53158-1. Sci Rep. 2024. PMID: 38291115 Free PMC article.
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
Sugiyama Y, Naiki T, Tasaki Y, Mimura Y, Etani T, Noda Y, Nozaki S, Shimizu N, Banno R, Nagai T, Isobe T, Ando R, Moritoki Y, Kataoka T, Odagiri K, Aoki M, Gonda M, Yasui T, Hibi Y. Sugiyama Y, et al. Among authors: isobe t. Oncology. 2023;101(4):224-233. doi: 10.1159/000529203. Epub 2023 Jan 23. Oncology. 2023. PMID: 36689919
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: isobe t. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
A Multicenter, Prospective, Non-randomized Study Evaluating Surgical hand Preparation between Double-Gloving and Single-Gloving for Preventing Postoperative Infection in Robotic and Laparoscopic Minimally Invasive Surgeries.
Nagai T, Taguchi K, Isobe T, Matsuyama N, Hattori T, Unno R, Kato T, Etani T, Hamakawa T, Fujii Y, Ikegami Y, Kamiya H, Hamamoto S, Nakane A, Ando R, Maruyama T, Okada A, Kawai N, Yasui T. Nagai T, et al. Among authors: isobe t. Urol J. 2023 Feb 27;20(2):109-115. doi: 10.22037/uj.v19i.7239. Urol J. 2023. PMID: 36127829 Free article.
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N, Aoki M, Gonda M, Banno R, Kubota H, Ando R, Umemoto Y, Kawai N, Yasui T. Morikawa T, et al. Among authors: isobe t. Cancers (Basel). 2024 Apr 28;16(9):1725. doi: 10.3390/cancers16091725. Cancers (Basel). 2024. PMID: 38730675 Free PMC article.
11 results